Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.19

-4.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (10341)	2/8/2004 2:44:52 PM
From: quidditch	Read Replies (2) of 52153

Rick, <<...a resounding YES>>, (:--( I guess the answer to the question as to whether the science guys, in those cases, follow the finance guys or power guys (founders, ceo's etc.) and do their bidding by designing "ambivalent" trials or are equally content to preserve their sinecure is a question of ethics and integrity throughout the organization. There must be times when it's very tough to determine whether it's the above (caliber and character of management), or the clinical results and therapeutic objective are just damn tough to get a handle on. Wonder where REGN fits in this? quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next